(Boursier.com) — Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company developing novel drugs that modulate the immune system to treat inflammatory diseases, viral diseases and cancer, held its Annual Ordinary and Extraordinary General Meeting on June 9 2022, under the chairmanship of Pr. Hartmut Ehrlich, MD, CEO of Abivax, in the absence of the Chairman of the Board of Directors.
The resolutions presented by the Board of Directors were adopted and in particular, the approval of the financial statements for the year ended December 31, 2021, the compensation policy applicable to the Chairman of the Board of Directors, the Chief Executive Officer and the directors , as well as the delegations granted to the Board of Directors in financial matters.
The Meeting also approved the renewal of the directorships of Jean-Jacques Bertrand, Pr. Carol L. Brosgart, MD, Joy Amundson and Sofinnova Partners.
Details of the results of the vote on all resolutions will be available on the company’s website.
©2022 Boursier.com